Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways

Pain ◽  
2015 ◽  
Vol 156 (2) ◽  
pp. 305-317 ◽  
Author(s):  
Martha Lopez-Canul ◽  
Enza Palazzo ◽  
Sergio Dominguez-Lopez ◽  
Livio Luongo ◽  
Baptiste Lacoste ◽  
...  
2015 ◽  
Vol 21 (13) ◽  
pp. 1723-1740 ◽  
Author(s):  
Katarzyna Panczyk ◽  
Sylwia Go.lda ◽  
Anna Waszkielewicz ◽  
Dorota Zelaszczyk ◽  
Agnieszka Gunia-Krzyz.ak ◽  
...  

Pain ◽  
2008 ◽  
Vol 139 (1) ◽  
pp. 117-126 ◽  
Author(s):  
Maria Osikowicz ◽  
Joanna Mika ◽  
Wioletta Makuch ◽  
Barbara Przewlocka

2021 ◽  
Author(s):  
Benjamin E Blass ◽  
Rong Gao ◽  
Kevin M. Blattner ◽  
John C. Gordon ◽  
Douglas A. Pippin ◽  
...  

Abstract Nearly 40 years after the first disclosure of sigma receptors, the sigma-2 (σ2) receptor was recently identified as the Transmembrane Protein 97 (TMEM97, also known as MAC30 (Meningioma-associated protein). This macromolecule has been associated with a number of disease states such as schizophrenia, Alzheimer’s disease, neuropathic pain, traumatic brain injury, and cancer. We have recently identified a series of novel, functionalized γ-butyrolactones that are potent σ2 receptor ligands that are drug-like and identified a potential candidate (9z) for future in vivo study.


2010 ◽  
Vol 20 ◽  
pp. S567
Author(s):  
F. Viguier ◽  
B. Michot ◽  
V. Kayser ◽  
M. Hamon ◽  
S. Bourgoin

2005 ◽  
Vol 38 (10) ◽  
pp. 15
Author(s):  
Sherry Boschert
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document